What is RenehaVis?
RenehaVis is a product designed to relieve pain and stiffness of the knee joint in patients with degenerative changes to the synovial joint, with proven 12 months efficacy. Furthermore, this Renehavis 1,4 ml for sale, product contains 2 different Hyaluronic Acids with 2 different concentrations in 1 syringe. SHORTER TREATMENT AND BETTER RECOVERY OF OSTEOARTHRITIS.
Note that Renehavis 1,4 ml for sale is a modern treatment for pain and mobility issues in the knee and hip joints, caused by arthrosis. Authentic Renehavis 1,4 ml for sale is highly effective and is the only unique two-chamber injection that administrate two forms of hyaluronic acid (HA) in a single injection, which improves elasticity and alleviate the pain in the joints.
Presence of the two forms of Hyaluronic acid (low molecular and high molecular) and also ensures the best effect on the body’s own hyaluronic acid, which under normal conditions is produced in healthy joints.
The pack consists of:
1 x 1,4 ml dual chambered syringe
Champer 1: 0,7 ml Sterile 2.2% sodium hyaluronate (Low molecular weight)
Also Champer 2: 0,7 ml sterile 1,0% Sodium hyaluronate (High molecular weight)
Benefits of Juvéderm Volux Lidocaine:
Treats pain caused by osteoarthritis
Improves mobility and elasticity
How long does the results last for? The Renehavis 1,4 ml for sale effects may lasts up to at least 12 months after a full treatment of 2 injections.
MTD Int’l SA was established in 2007, with the aim of providing a wide range of medical devices in the highest quality. MTD Int’l SA is an innovative company that is dedicated to the development of wide range of medical devices used in a number of specialized therapeutic areas among other orthopedics, soft tissue recovery. Their products are innovative and absolute safe.
MTD is the manufacturer of RenehaVis – a product designed to relieve pain and stiffness of the knee joint in patients with degenerative changes in the synovial joint, including osteoarthritis.
RenehaVis is two clear solutions of sterile sodium hyaluronate in a phosphate buffer saline contained in a dual chamber prefill syringe for single intra-articular injection into the synovial space of the joint.
RenehaVis LMW Sodium hyaluronate 15.4mg/0.7ml and HMW Sodium hyaluronate 7.0mg/0.7ml For the relief of the symptoms of osteoarthritis of the knee by providing support and lubrication to the knee joint.
RenehaVis 0.7ml LMW and 0.7ml HMW, terminally sterilise by moist heat, is enclose within a glass, ready-to-use, disposable syringe. The syringe is pack within a blister pack and an outer cardboard carton.
RenehaVis is a sterile pre-filled dual-chamber, glass ready-to-use disposable syringe containing:
Chamber 1 >
Sodium hyaluronate Low Molecular Weight
(LMW): 0.7ml sterile 2.2% sodium hyaluronate
1×106 Da molecular weight.
Chamber 2 >
Sodium hyaluronate High Molecular Weight
(HMW): 0.7ml sterile 1.0% sodium
Dosage and Administration
Injection of RenehaVis should only be made by a Healthcare Professional trained in the technique.
The dosage regimen is inject into the affect synovial joint space once a week for up to three injections depending on the severity of the degenerative change to the knee joint.
Clean the skin around the injection site with antiseptic and allow to dry before injection is given. If joint effusion is present it should be aspirate prior to injection of RenehaVis.
Aspiration of a small amount of synovial fluid as part of the injection procedure to ensure the correct positioning of the needle is possible. Before proceeding, ensure that the plunger rod is tightly screw into the plunger stopper.
The contents of the syringe are sterile and should be inject using a sterile needle of an appropriate size (25 gauge needle is recommended). The syringe is fitted with a Luer lock (6%). Discard the syringe and needle after single use.
For the relief of pain and stiffness of the knee joint in patients with degenerative changes to the synovial joint. The duration of effect in patients with grade 1 to 3 medial compartment osteoarthritis has been demonstrated to be up to 12 months.
The performance of RenehaVis is due to its biocompatibility and physicochemical properties. The LMW and HMW sodium hyaluronate contained in RenehaVis is a biopolymer composed of repeating disaccharide units of N-acetylglucosamine and glucuronic acid and though it is biosynthesise by the bacterium Streptococcus equi it has been shown to be the same as the sodium hyaluronate which is found in the human body. RenehaVis supplements the endogenous Sodium Hyaluronate found naturally in the synovium but which has been depleted by degenerative and traumatic changes to the synovial joint.
Contra-indications, Patients with known sensitivity to sodium hyaluronate.
Warnings and Precautions
Do not inject RenehaVis if the area of the injection is infect or where there is evidence of skin disease. quality RenehaVis pre-fill syringe is single use. The contents of the syringe should be used for one injection only. Any remaining sodium hyaluronate should be discard. If a syringe is retain for a subsequent injection there is a risk of contamination resulting in the possible infection of the patient and/or foreign body reaction. RenehaVis should not be resterilise as the device performance may be compromised which could cause serious harm to the patient’s health and safety. Sodium hyaluronate is manufactured by fermentation of Streptococcus equi and rigorously purify. However, the physician should consider the immunological and potential risks that can be associate with the injection of any biological material.
Do not use in children. There is no evidence concerning the safety of RenehaVis in human pregnancy and lactation. Administration during pregnancy and lactation is at the discretion of the orthopedic surgeon. Do not use if sterile packaging has been damage. Do not use after the expiry date list on the package. Follow national or local guidelines for the safe use and disposal of needles. Obtain prompt medical attention if injury occurs.
Transient pain and swelling may occur with intra-articular injections.
Transient increases in inflammation in the inject synovial joint following injection of RenehaVis may occur in patients with inflammatory osteoarthritis. Rarely an inflammatory reaction could occur which may or may not be associated with RenehaVis.
The RenehaVis has not been tested for compatibility with other substances for intra-articular injection. Therefore the mixing or simultaneous administration with other intra-articular injectables is not recommend.
Store between 2°C and 25°C.
Protect from light.
Do not use if sterile packaging has been damaged.
Avoid to use after expiry date.